Loading...
Transcatheter aortic valve replacement (TAVR) is currently approved for patients with severe symptomatic aortic stenosis and high or intermediate surgical risk, and approval is expected soon for patients at low surgical risk. Although specific center requirements (including annual procedural volumes) exist for obtaining reimbursement from the Centers for Medicare and Medicaid Services, these requirements are currently under scrutiny. And while previous studies have demonstrated improved outcomes at higher-volume centers, these studies were based on early-generation technology and might have captured the learning curves of new centers. To examine whether a volume–outcome relationship for TAVR still exists, investigators analyzed 2015–2017 da…